Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results

BACKGROUND: Radiolabelled antibody targeting of cancer is limited by slow blood clearance. Pretargeting with a non-radiolabelled bispecific monoclonal antibody (bsMAb) followed by a rapidly clearing radiolabelled hapten peptide improves tumour localisation. The primary goals of this first pretargeti...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Schoffelen, R, Boerman, O C, Goldenberg, D M, Sharkey, R M, van Herpen, C M L, Franssen, G M, McBride, W J, Chang, C-H, Rossi, E A, van der Graaf, W T A, Oyen, W J G
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2013
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3749562/
https://ncbi.nlm.nih.gov/pubmed/23860529
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.376
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items